Literature DB >> 33189904

Assessment of response to multimodal management of neurotrophic corneal disease.

Tanya Trinh1, Gisella Santaella1, Michael Mimouni1, Zale Mednick1, Eyal Cohen1, Nir Sorkin2, David S Rootman1, Allan R Slomovic1, Clara C Chan3.   

Abstract

PURPOSE: To characterize patients with neurotrophic keratopathy (NK) and describe treatment outcomes.
METHODS: Setting: Two institutional tertiary cornea clinics. PATIENTS: Medical record review of 37 consecutive patients (37 eyes) with NK. INTERVENTION: Management of NK. MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA), epithelial defects (ED), re-epithelialization time, number of perforations, need for penetrating keratoplasty and tarsorrhaphy.
RESULTS: Average age was 64.4 ± 15.0 years, with 59.5% male patients. Average follow up time was 20.8 ± 32.6 months. Moderate to severe NK (Mackie Stage) was present in 62.1% of patients. Herpetic, neurosurgical and pars plana vitrectomy were the top three causes in each Mackie Stage. 72.9% used topical steroids to treat inflammatory ocular disease. Mean number of EDs was 1.6 per patient averaging 85 days to heal. Persistent EDs affected 56.7%. Corneal perforation (18.9%) was more likely with advanced age, herpetic cause and Stage 3 presentation. Tarsorrhaphy was performed in 35% of patients and were more likely with Stage 3 presentation. Referral for neurotization occurred in 10.8%. Evisceration was required in 2 eyes. BCVA of 20/40 or better was achieved in 21.6% of eyes at last follow up.
CONCLUSIONS: NK is chronic, frequently visually disabling with multiple contributing factors requiring different treatment modalities. Herpetic, pars plana vitrectomy and neurosurgical causes constitute a significant proportion of NK. Persistent epithelial defects should be rapidly managed as corneal perforation is a serious complication. Advanced age, herpetic cause and Mackie Stage 3 at diagnosis are significant risk factors for corneal perforation.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Herpetic keratitis; Neuroparalytic keratitis; Neurotrophic cornea; Neurotrophic keratitis; Ocular surface disease; Trigeminal nerve disease

Mesh:

Year:  2020        PMID: 33189904     DOI: 10.1016/j.jtos.2020.11.003

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  4 in total

Review 1.  Corneal neurotization for neurotrophic keratopathy: Review of surgical techniques and outcomes.

Authors:  Catherine Y Liu; Andrea C Arteaga; Sammie E Fung; M Soledad Cortina; Ilya M Leyngold; Vinay K Aakalu
Journal:  Ocul Surf       Date:  2021-02-26       Impact factor: 5.033

2.  Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis.

Authors:  Sébastien Roumeau; Frédéric Dutheil; Vincent Sapin; Julien S Baker; Stephanie L Watson; Bruno Pereira; Frédéric Chiambaretta; Valentin Navel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-07       Impact factor: 3.535

3.  Entry receptor bias in evolutionarily distant HSV-1 clinical strains drives divergent ocular and nervous system pathologies.

Authors:  Lulia Koujah; Mowafak Allaham; Chandrashekhar D Patil; Joshua M Ames; Rahul K Suryawanshi; Tejabhiram Yadavalli; Alex Agelidis; Christine Mun; Bayasgalan Surenkhuu; Sandeep Jain; Deepak Shukla
Journal:  Ocul Surf       Date:  2021-03-22       Impact factor: 6.268

Review 4.  New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis.

Authors:  Su Yin Koay; Daniel F P Larkin
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.